GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Repligen Corp (FRA:RGN) » Definitions » EV-to-EBITDA

Repligen (FRA:RGN) EV-to-EBITDA : 76.54 (As of May. 30, 2025)


View and export this data going back to . Start your Free Trial

What is Repligen EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Repligen's enterprise value is €6,106.1 Mil. Repligen's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 was €79.8 Mil. Therefore, Repligen's EV-to-EBITDA for today is 76.54.

The historical rank and industry rank for Repligen's EV-to-EBITDA or its related term are showing as below:

FRA:RGN' s EV-to-EBITDA Range Over the Past 10 Years
Min: 31   Med: 63.18   Max: 125.23
Current: 79.19

During the past 13 years, the highest EV-to-EBITDA of Repligen was 125.23. The lowest was 31.00. And the median was 63.18.

FRA:RGN's EV-to-EBITDA is ranked worse than
92.71% of 494 companies
in the Medical Devices & Instruments industry
Industry Median: 15.78 vs FRA:RGN: 79.19

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2025-05-30), Repligen's stock price is €107.70. Repligen's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 was €-0.397. Therefore, Repligen's PE Ratio (TTM) for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).


Repligen EV-to-EBITDA Historical Data

The historical data trend for Repligen's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Repligen EV-to-EBITDA Chart

Repligen Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 103.57 70.91 33.20 68.72 99.71

Repligen Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 72.53 55.26 70.85 99.71 82.38

Competitive Comparison of Repligen's EV-to-EBITDA

For the Medical Instruments & Supplies subindustry, Repligen's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Repligen's EV-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Repligen's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Repligen's EV-to-EBITDA falls into.


;
;

Repligen EV-to-EBITDA Calculation

Repligen's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=6106.144/79.772
=76.54

Repligen's current Enterprise Value is €6,106.1 Mil.
Repligen's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €79.8 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Repligen  (FRA:RGN) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Repligen's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=107.70/-0.397
=At Loss

Repligen's share price for today is €107.70.
Repligen's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.397.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?


Repligen EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Repligen's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Repligen Business Description

Traded in Other Exchanges
Address
41 Seyon Street, Building 1, Suite 100, Waltham, MA, USA, 02453
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.

Repligen Headlines

No Headlines